FDA again targets GLP-1 compounders; Intellia to restart heart disease trial
Source: BioPharma Dive - Latest News
The agency zeroed in on claims that compounded GLP-1 drugs are comparable to approved medicines. Elsewhere, a blood pressure drug topped Wall Street expectations and a Merck deal paid dividends.